Financial Performance
Artemis Medicare Services Limited reported strong FY26 results with consolidated revenue growing 15.4% to ₹1,081.24 crore and profit after tax increasing 26.2% to ₹103.72 crore. The company achieved EBITDA of ₹218.01 crore with a 20.2% margin, while EPS (basic) stood at ₹6.56. Operational metrics showed 63.0% occupancy rate and ARPOB improvement to ₹82,435 from ₹76,447 year-on-year.
Capital Structure & Corporate Actions
The company completed conversion of ₹330 crore Compulsorily Convertible Debentures (CCDs) issued to International Finance Corporation, resulting in issuance of 1,89,62,247 equity shares at ₹174.03 per share. This increased share capital by ₹1.89 crore and securities premium by ₹328.10 crore. The board recommended a final dividend of ₹0.45 per share, subject to shareholder approval at the upcoming AGM.
Expansion & Operational Highlights
Artemis operationalized its third tower at Gurugram, augmenting bed capacity to 700 beds, and received IGBC Platinum Green Building certification. The company announced significant expansion plans including a 300+ bed facility in Raipur (expected FY2027) and a 650+ bed project in South Delhi under "VIMHANS ARTEMIS HOSPITAL" brand (expected FY2029), targeting approximately 2,000 beds by 2028. The company maintained JCI and NABH accreditations and launched new programs including heart and lung transplant collaboration and 5G-enabled ambulance service.
AGM & Governance
The 22nd Annual General Meeting will be held virtually on July 31, 2026, with key resolutions including adoption of financial statements, dividend declaration, appointment of two new independent directors (Mr. Tapan Mitra and Dr. Girdhar Jessaram Gyani), re-appointment of statutory auditors for five years, and approval of commission payments to non-executive directors. The record date for dividend is July 10, 2026.
Financial Position & Ratios
The company maintained a healthy balance sheet with total assets of ₹1,420.61 crore and debt-equity ratio of 0.26. Current ratio stood at 1.74 times while return on equity was 12.60%. The company had cash and equivalents of ₹33.41 crore and made capital expenditures of ₹107.24 crore during the year.
Regulatory & Compliance Matters
The financial statements received unmodified audit opinion from T R Chadha & Co LLP. The company faces several contingent liabilities including GST demand notice of ₹630.45 crore (under dispute), income tax matters of ₹105.49 crore, and patient compensation claims of ₹316.86 crore (adequately insured). CSR expenditure of ₹1.50 crore was incurred on various initiatives including rainwater conservation and tuberculosis elimination programs.